Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

By Nikita Chaurasia  | Date: 2021-03-25

Pfizer begins Phase-1 trials of oral COVID-19 antiviral drug in U.S.

Pfizer Inc., an American multinational pharmaceutical corporation, has recently announced to have started the early phase trials for its oral antiviral drug for Coronavirus. The company revealed that first phase trials of the experimental drug, PF-07321332, are currently being conducted in the U.S.

The new drug pertains to the protease inhibitor class of antiviral drugs and can prevent viral replication in human cells, by blocking the production of an enzyme. For those unaware, protease inhibitors are commonly used for the treatment of viral pathogens like Hepatitis C and HIV.

Chief Scientific Officer of Pfizer, Mikael Dolsten reportedly said that both modes of prevention using vaccines and treatment for those affected with the virus are equally important to manage the coronavirus pandemic. The rapid mutation of SARS-CoV-2 along with the continued impact of the ongoing pandemic has necessitated access to curative measures in the long run.

The phase one trials for the oral antiviral drug are being performed in tandem with Pfizer’s development of PF-07304814, an intravenously administered protease inhibitor. The drug is currently in a phase 1 B clinical trial and is currently being tested on patients admitted in hospitals with COVID-19.

Even though drugmakers such as BioNTech and Pfizer have had their vaccines approved in the United States, analysts opine that the world will require a variety of drugs to arrest the pandemic.

Meanwhile, preclinical studies have exhibited that the oral drug, which is the first protease inhibitor to be analyzed in clinical trials, has a strong antiviral capacity against the virus, according to the firm.

The drug may be recommended to individuals who are newly infected with the virus as it can be ingested orally. Researchers hope that the drug will slow the progression of the disease and keep people out of the hospital.

Pfizer divulged that it would provide more information on the drug’s progress on 6th April 2021 at the American Chemical Society Spring Meeting.

Source Credit –

https://www.news18.com/news/world/pfizer-starts-early-stage-clinical-trial-testing-of-oral-antiviral-drug-for-coronavirus-report-3566318.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...